Last updated: February 25, 2026
What is NDC 00378-5270?
NDC 00378-5270 corresponds to Tafinlar (dabrafenib), a targeted therapy approved by the FDA for BRAF V600E mutation-positive melanoma, non-small cell lung cancer (NSCLC), and other BRAF-mutated tumors. Produced by Novartis, it is marketed as a monotherapy and in combination with Mekinist (trametinib).
Market Landscape Overview
Existing Market Players
- Novartis: Dominant provider with global distribution.
- Generics: No generic version available as of 2023, due to patent exclusivity.
- Competitive drugs:
- Zelboraf (vemurafenib): BRAF inhibitor.
- Lorbrena (lorlatinib): For ALK-positive NSCLC, competing indirectly.
- Key Targeted Therapies: MEK inhibitors, immune checkpoint inhibitors like pembrolizumab.
Indications and Market Size
- Metastatic melanoma: Estimated 7,000 new cases annually in the U.S.
- NSCLC with BRAF V600E mutation: Approx. 1-2% of NSCLC cases; roughly 20,000 cases nationally.
- Other cancers: Including hairy cell leukemia and others, smaller markets.
Distribution Channels
- Specialty pharmacies dominate.
- Oncology clinics primarily dispense.
- Reimbursement through Medicare, Medicaid, private insurers.
Regulatory Considerations
- Patent protection extends until 2029.
- No significant biosimilar presence expected before patent expiry.
- Ongoing clinical trials exploring new indications.
Market Trends
- Increasing Precision Medicine Adoption: Growing use of genetic testing leads to higher prescription rates.
- Combination Therapies: Use of dabrafenib with trametinib is standard, influencing market volume.
- Pricing Strategies: Premium pricing maintained through patent protections and clinical efficacy.
Price Projections
Current Pricing
- Wholesale acquisition cost (WAC) for Tafinlar approximately $9,800 per 28-day supply.
- Average retail price: around $10,200 per month.
- Cost varies by dosage and form (oral capsules).
Future Price Trends
| Year |
Estimated Price Range (per 28-day supply) |
Assumptions |
| 2023 |
$9,800 - $10,200 |
Stable, no new biosimilars, patent protection active. |
| 2024-2025 |
$10,000 - $11,000 |
Slight inflation, new indications expanding market, potential payor negotiations. |
| 2026-2029 |
$11,500 - $13,000 |
Approaching patent expiry, market pressure increases, possible biosimilar entry in late 2029. |
Impact of Patent Expiry
Biosimilar entry predicted post-2029 could reduce prices by 20-40%. However, launch timelines are speculative; market penetration depends on regulatory approval and prescriber acceptance.
Reimbursement and Insurance Coverage
Reimbursement remains high due to FDA approval and clinical necessity. Price negotiations with payers could moderate future prices but likely not significantly before patent expiry.
Key Market Drivers and Challenges
-
Drivers:
- Increasing genetic testing.
- Adoption of combination therapies.
- Expansion into new oncology indications.
-
Challenges:
- High drug cost affects payer acceptance.
- Long development timelines for competing therapies.
- Market saturation in core indications.
Key Takeaways
- NDC 00378-5270 (Tafinlar/dabrafenib) holds a dominant position in BRAF V600E mutation-positive melanoma and NSCLC.
- Price remains stable around $10,000 per month, with incremental increases expected up to patent expiration.
- Clinical and regulatory factors, including patent expiration and biosimilar development, will influence future pricing.
- Market growth correlates with increasing genetic diagnostics and combination use.
- Potential entry of biosimilars post-2029 could significantly alter the competitive landscape and pricing.
FAQs
Q1: When does the patent for dabrafenib expire?
A1: Patent protection extends until 2029, after which biosimilars may enter the market.
Q2: What are the primary clinical trials influencing the market?
A2: Trials demonstrating efficacy in melanoma and NSCLC; ongoing studies explore additional BRAF-mutant cancers.
Q3: How does the pricing compare with similar targeted therapies?
A3: Dabrafenib’s current price is comparable to other targeted oncology drugs, typically falling within $9,000 to $11,000 per month.
Q4: What are the key factors influencing future market growth?
A4: Increased genetic testing, new approved indications, and combination therapies.
Q5: How might biosimilar entry impact the market?
A5: Entry post-2029 could decrease prices by 20-40%, depending on regulatory approval and market adoption.
References
[1] U.S. Food and Drug Administration (FDA). (2018). Approval of Tafinlar (dabrafenib). Retrieved from https://www.fda.gov
[2] IQVIA. (2022). Global Oncology Market Analysis.
[3] Novartis. (2023). Tafinlar (dabrafenib) prescribing information.
[4] IMS Health. (2022). Oncology Drug Pricing Data.
[5] National Cancer Institute. (2022). BRAF mutation-positive cancers.
